[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse ARF6

Summary
SymbolARF6
NameADP-ribosylation factor 6
Aliases
Chromosomal Location14q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytosol Cell membrane Lipid-anchor Endosome membrane Lipid-anchor. Recycling endosome membrane Lipid-anchor Cell projection, filopodium membrane; Lipid-anchor. Cell projection, ruffle Cleavage furrow Midbody, Midbody ring Golgi apparatus Note=Distributed uniformly on the plasma membrane, as well as throughout the cytoplasm during metaphase. Subsequently concentrated at patches in the equatorial region at the onset of cytokinesis, and becomes distributed in the equatorial region concurrent with cleavage furrow ingression. In late stages of cytokinesis, concentrates at the midbody ring/Flemming body (PubMed:23603394). Recruitement to the midbody ring requires both activation by PSD/EFA6A and interaction with KIF23/MKLP1 (By similarity). After abscission of the intercellular bridge, incorporated into one of the daughter cells as a midbody remnant and localizes to punctate structures beneath the plasma membrane (PubMed:23603394). Recruited to the cell membrane in association with CYTH2 and ARL4C. Colocalizes with DAB2IP at the plasma membrane and endocytic vesicles (By similarity). Myristoylation is required for proper localization to membranes (PubMed:7589240).
Domain PF00025 ADP-ribosylation factor family
Function

GTP-binding protein involved in protein trafficking that regulates endocytic recycling and cytoskeleton remodeling (PubMed:11266366, PubMed:21170023, PubMed:16737952, PubMed:7589240, PubMed:18400762). Required for normal completion of mitotic cytokinesis (By similarity). Plays a role in the reorganization of the actin cytoskeleton and the formation of stress fibers (By similarity). May also modulate vesicle budding and uncoating within the Golgi apparatus. Involved in the regulation of dendritic spine development, contributing to the regulation of dendritic branching and filopodia extension (PubMed:14978216). Plays an important role in membrane trafficking, during junctional remodeling and epithelial polarization. Regulates surface levels of adherens junction proteins such as CDH1 (By similarity). ; FUNCTION: (Microbial infection) Functions as an allosteric activator of the cholera toxin catalytic subunit, an ADP-ribosyltransferase.

> Gene Ontology
 
Biological Process GO:0001889 liver development
GO:0006898 receptor-mediated endocytosis
GO:0007009 plasma membrane organization
GO:0007015 actin filament organization
GO:0007163 establishment or maintenance of cell polarity
GO:0007265 Ras protein signal transduction
GO:0008064 regulation of actin polymerization or depolymerization
GO:0008154 actin polymerization or depolymerization
GO:0010721 negative regulation of cell development
GO:0010975 regulation of neuron projection development
GO:0010977 negative regulation of neuron projection development
GO:0016358 dendrite development
GO:0016601 Rac protein signal transduction
GO:0030010 establishment of cell polarity
GO:0030031 cell projection assembly
GO:0030041 actin filament polymerization
GO:0030100 regulation of endocytosis
GO:0030832 regulation of actin filament length
GO:0030833 regulation of actin filament polymerization
GO:0030838 positive regulation of actin filament polymerization
GO:0030865 cortical cytoskeleton organization
GO:0030866 cortical actin cytoskeleton organization
GO:0031334 positive regulation of protein complex assembly
GO:0031345 negative regulation of cell projection organization
GO:0031529 ruffle organization
GO:0032271 regulation of protein polymerization
GO:0032273 positive regulation of protein polymerization
GO:0032535 regulation of cellular component size
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0033028 myeloid cell apoptotic process
GO:0034394 protein localization to cell surface
GO:0035020 regulation of Rac protein signal transduction
GO:0036010 protein localization to endosome
GO:0043254 regulation of protein complex assembly
GO:0044089 positive regulation of cellular component biogenesis
GO:0045665 negative regulation of neuron differentiation
GO:0045806 negative regulation of endocytosis
GO:0046578 regulation of Ras protein signal transduction
GO:0046847 filopodium assembly
GO:0048259 regulation of receptor-mediated endocytosis
GO:0048261 negative regulation of receptor-mediated endocytosis
GO:0048732 gland development
GO:0050768 negative regulation of neurogenesis
GO:0050773 regulation of dendrite development
GO:0051051 negative regulation of transport
GO:0051056 regulation of small GTPase mediated signal transduction
GO:0051258 protein polymerization
GO:0051489 regulation of filopodium assembly
GO:0051493 regulation of cytoskeleton organization
GO:0051495 positive regulation of cytoskeleton organization
GO:0051961 negative regulation of nervous system development
GO:0060491 regulation of cell projection assembly
GO:0060627 regulation of vesicle-mediated transport
GO:0060996 dendritic spine development
GO:0060998 regulation of dendritic spine development
GO:0061008 hepaticobiliary system development
GO:0072657 protein localization to membrane
GO:0072659 protein localization to plasma membrane
GO:0072665 protein localization to vacuole
GO:0090002 establishment of protein localization to plasma membrane
GO:0090003 regulation of establishment of protein localization to plasma membrane
GO:0090004 positive regulation of establishment of protein localization to plasma membrane
GO:0090066 regulation of anatomical structure size
GO:0090150 establishment of protein localization to membrane
GO:0090162 establishment of epithelial cell polarity
GO:0097284 hepatocyte apoptotic process
GO:1903076 regulation of protein localization to plasma membrane
GO:1903078 positive regulation of protein localization to plasma membrane
GO:1903729 regulation of plasma membrane organization
GO:1903829 positive regulation of cellular protein localization
GO:1904019 epithelial cell apoptotic process
GO:1904375 regulation of protein localization to cell periphery
GO:1904377 positive regulation of protein localization to cell periphery
GO:1904951 positive regulation of establishment of protein localization
GO:1990778 protein localization to cell periphery
GO:2000171 negative regulation of dendrite development
Molecular Function GO:0003924 GTPase activity
GO:0005525 GTP binding
GO:0019001 guanyl nucleotide binding
GO:0031996 thioesterase binding
GO:0032561 guanyl ribonucleotide binding
GO:0047485 protein N-terminus binding
Cellular Component GO:0001726 ruffle
GO:0005769 early endosome
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0005938 cell cortex
GO:0010008 endosome membrane
GO:0030055 cell-substrate junction
GO:0030139 endocytic vesicle
GO:0030175 filopodium
GO:0030496 midbody
GO:0031252 cell leading edge
GO:0031253 cell projection membrane
GO:0031527 filopodium membrane
GO:0032153 cell division site
GO:0032154 cleavage furrow
GO:0032155 cell division site part
GO:0043209 myelin sheath
GO:0044440 endosomal part
GO:0055037 recycling endosome
GO:0055038 recycling endosome membrane
GO:0097610 cell surface furrow
GO:0098858 actin-based cell projection
GO:0099568 cytoplasmic region
> KEGG and Reactome Pathway
 
KEGG hsa04014 Ras signaling pathway
hsa04144 Endocytosis
hsa04666 Fc gamma R-mediated phagocytosis
Reactome R-HSA-8856828: Clathrin-mediated endocytosis
R-HSA-8875656: MET receptor recycling
R-HSA-199991: Membrane Trafficking
R-HSA-162582: Signal Transduction
R-HSA-6806834: Signaling by MET
R-HSA-8854214: TBC/RABGAPs
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolARF6
NameADP-ribosylation factor 6
Aliases
Chromosomal Location14q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ARF6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolARF6
NameADP-ribosylation factor 6
Aliases
Chromosomal Location14q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ARF6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -2.16; FDR: 0.04170 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.18; FDR: 0.04220 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolARF6
NameADP-ribosylation factor 6
Aliases
Chromosomal Location14q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ARF6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1410.56
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3890.876
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0380.983
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3060.335
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2740.896
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3480.897
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0730.863
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0410.983
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1080.961
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2060.894
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5920.798
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0060.928
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ARF6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolARF6
NameADP-ribosylation factor 6
Aliases
Chromosomal Location14q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ARF6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolARF6
NameADP-ribosylation factor 6
Aliases
Chromosomal Location14q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ARF6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ARF6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolARF6
NameADP-ribosylation factor 6
Aliases
Chromosomal Location14q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ARF6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolARF6
NameADP-ribosylation factor 6
Aliases
Chromosomal Location14q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ARF6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolARF6
NameADP-ribosylation factor 6
Aliases
Chromosomal Location14q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ARF6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolARF6
NameADP-ribosylation factor 6
Aliases
Chromosomal Location14q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ARF6 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ARF6.
ID Name Drug Type Targets #Targets
DB018645'-Guanosine-Diphosphate-MonothiophosphateSmall MoleculeARF6, RAB11A, TGM33
DB04315Guanosine-5'-DiphosphateSmall MoleculeADSSL1, ARF1, ARF4, ARF6, ARL1, ARL3, ARL5A, ARL5B, CDC42, EEF1A1, ......36
DB08231Myristic acidSmall MoleculeABL1, ARF1, ARF6, ECI2, FKBP1A, GM2A, GUCA1A, HNF4A, INS, LY96, NC ......20